[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335690-105":59,"doc-detail-335690-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prevalence-and-significance-of-incidental-petct-findings-of-cancer-detected-in-patients-evaluated-for-their-primary-hematologic-malignancy-a-systematic-review","Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy - A Systematic Review","","A systematic review evaluates positron emission tomography/computed tomography (PET/CT)–detected incidental abnormalities suggestive of a second concurrent cancer in patients assessed for primary hematologic malignancies. Using MEDLINE and Embase, the review summarizes prevalence and clinical significance across 13 studies published from 2008 to 2022. Clinically significant incidental cancers show a median prevalence of 2.4% (range 1.1–10.3%) in myeloma/plasma cell disorders versus 1.5% (range 0.3–2.8%) in lymphoproliferative diseases. Most clinically significant sites occur in the gastrointestinal tract (44.4%), then the thyroid (22.2%) and lungs (7.9%).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prevalence-and-significance-of-incidental-petct-findings-of-cancer-detected-in-patients-evaluated-for-their-primary-hematologic-malignancy-a-systematic-review/335690/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prevalence-and-significance-of-incidental-petct-findings-of-cancer-detected-in-patients-evaluated-for-their-primary-hematologic-malignancy-a-systematic-review/335690.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical issue does the review address regarding PET/CT scans?","Question",{"text":112,"@type":113},"Incidental PET/CT findings may suggest a second concurrent cancer when evaluating a patient’s primary hematologic malignancy, requiring assessment and sometimes biopsy to confirm significance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the prevalence and significance of incidental findings studied?",{"text":117,"@type":113},"The review used a systematic search strategy on MEDLINE and Embase and included 13 studies published between 2008 and 2022, including conference abstracts and journal articles.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the reported prevalence differences between patient groups?",{"text":121,"@type":113},"Clinically significant incidental cancers occurred with a median of 2.4% (range 1.1–10.3%) in myeloma/plasma cell disorders and 1.5% (range 0.3–2.8%) in lymphoproliferative diseases.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335690,1790100040,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Systematic Review  \nPrevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review  \nJessie Luo 1, Nizar J. Bahlis 2,3, Denise Chan 4, Peter Duggan 2,3, Victor H. Jimenez-Zepeda 2,3, Holly Lee 2, Sylvia McCulloch 2,3, Paola Neri 2,3 and Jason Tay 2,3, *  \nCitation: Luo, J.; Bahlis, N.J.; Chan, D.; Duggan, P.; Jimenez-Zepeda, V.H.; Lee, H.; McCulloch, S.; Neri, P.; Tay, J. Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review. Curr. Oncol. 2024, 31, 7445–7458 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol31120550  \nReceived: 31 October 2024  \nRevised: 19 November 2024  \nAccepted: 22 November 2024  \nPublished: 24 November 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada  \n2 Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada; [sylvia.mcculloch@albertahealthservices.ca](sylvia.mcculloch@albertahealthservices.ca) (S.M.)  \n3 Arnie Charbonneau Cancer Institute, Calgary, AB T2N 4Z6, Canada  \n4 Department of Radiology, University of Calgary, Calgary, AB T2N 4Z5, Canada  \n* [Correspondence: jason.tay@albertahealthservices.ca](Correspondence: jason.tay@albertahealthservices.ca)  \nAbstract: In the evaluation of a patient’s primary hematologic malignancy, positron emission tomography/computed tomography (PET/CT) imaging may incidentally detect a concerning abnormality suggestive of a second concurrent cancer. Despite accounting for nearly 10% of all cancers diagnosed in Canada, there has yet to be a systematic review focused on the prevalence and significance of these incidental PET/CT findings in the context of primary hematologic malignancies. As such, a systematic search strategy was employed on MEDLINE and Embase to document the prevalence and clinical significance of incidental PET/CT findings suggestive of a second concurrent cancer detected in patients evaluated for their primary hematologic malignancy. Thirteen studies published between 2008 and 2022 were reviewed, including conference abstracts (n = 8) and journal articles (n = 5) . Clinically significant incidental cancers were detected with a median of 2.4%(range: 1.1–10.3%) in patients with myeloma/plasma cell disorders, compared to a median of 1.5%(range: 0.3–2.8%) in patients with lymphoproliferative diseases. The most common anatomic regions of clinically significant incidental malignancies were identified in the gastrointestinal tract (44.4%), followed by the thyroid gland (22.2%) and lungs (7.9%) . In most cases, early detection of incidental cancers led to successful early interventions. PET/CT scans occasionally identify second primary malignancies that require additional attention. These findings may affect the treatment of a patient’s primary hematologic malignancy, and as such, timely coordinated management is important for improved outcomes. This review may inform physicians and administrators of the risk of incidental second malignancies and may highlight a need for enhanced cancer treatment pathways.  \nKeywords: PET/CT; hematologic malignancies; incidental findings; myeloma/plasma cell disorder; lymphoproliferative diseases  \n1. Introduction  \nHematologic malignancies include lymphomas (Hodgkin’s, non-Hodgkin’s), leukemias (acute lymphocytic, chronic lymphocytic, acute myeloid), myelomas, myelodysplastic syndromes, and myeloproliferative neoplasms [1], a","cbCaihB561pcyEJT","https://ap.wps.com/l/cbCaihB561pcyEJT","pdf",1112360,14,"English","# Abstract\n# Introduction\n## PET/CT in hematologic malignancies\n## Incidental findings and clinical relevance","[{\"question\":\"What clinical issue does the review address regarding PET/CT scans?\",\"answer\":\"Incidental PET/CT findings may suggest a second concurrent cancer when evaluating a patient’s primary hematologic malignancy, requiring assessment and sometimes biopsy to confirm significance.\"},{\"question\":\"How was the prevalence and significance of incidental findings studied?\",\"answer\":\"The review used a systematic search strategy on MEDLINE and Embase and included 13 studies published between 2008 and 2022, including conference abstracts and journal articles.\"},{\"question\":\"What are the reported prevalence differences between patient groups?\",\"answer\":\"Clinically significant incidental cancers occurred with a median of 2.4% (range 1.1–10.3%) in myeloma/plasma cell disorders and 1.5% (range 0.3–2.8%) in lymphoproliferative diseases.\"}]","Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy - A Systematic Review | PDF",1790011949,35]